A hepatology clinic reviewing a stack of transient elastography reports this month will find a familiar pattern: F2-F3 fibrosis on biopsy or imaging, elevated liver enzymes, a patient already on metformin or a statin, and no FDA-approved drug beyond resmetirom that fits the picture. That gap is exactly why enrollment counters on ClinicalTrials.gov for GLP-1 receptor agonist NASH trials have become something clinicians and trial coordinators check as routinely as lab results. The question is no longer whether GLP-1 agonism affects liver histology — Phase 2 data already answered that — but which Phase 3 programs are far enough along to matter for practice within the next two to three years.
This summary tracks the current state of GLP-1 receptor agonist Phase 3 trials in non-alcoholic steatohepatitis (NASH), now more precisely termed metabolic dysfunction-associated steatohepatitis (MASH) under the 2023 nomenclature consensus. It focuses on enrollment status, primary endpoint design, and what the histologic surrogate data can and cannot tell a clinician about durable liver outcomes.
Why These Trials Matter Now
Resmetirom (Rezdiffra) received FDA accelerated approval in March 2024 for adults with MASH and moderate-to-advanced fibrosis (F2-F3), based on histologic surrogate endpoints under the same regulatory framework the agency has applied to other progressive liver diseases. That approval established a template: sponsors can seek accelerated approval using biopsy-based resolution and fibrosis endpoints, with confirmatory trials required to verify clinical benefit post-marketing.
GLP-1 and dual-agonist sponsors are now running the same playbook. The pharmacologic rationale is straightforward — GLP-1 receptor activation reduces hepatic steatosis through weight loss, improved insulin sensitivity, and direct effects on hepatocyte lipid handling, mechanisms detailed in the mechanism-focused literature on incretin receptor signaling. What Phase 3 trials are testing is whether that steatosis reduction translates into reproducible, biopsy-confirmed resolution of steatohepatitis and fibrosis regression at a scale sufficient to support a labeled indication.
ESSENCE: Semaglutide's Phase 3 MASH Program
ESSENCE (NCT04822181) is the largest and most advanced GLP-1 receptor agonist trial in histology-confirmed MASH. Novo Nordisk designed it as a randomized, double-blind, placebo-controlled, parallel-group study of subcutaneous semaglutide 2.4 mg weekly against placebo, enrolling approximately 1,200 adults with biopsy-confirmed MASH and fibrosis stages F2 or F3, recruited across dozens of countries.
The trial uses two co-primary histologic endpoints assessed at week 72 by blinded central pathologists:
- Resolution of steatohepatitis (NAS score reduction meeting resolution criteria) without worsening of fibrosis stage
- Improvement in fibrosis stage of at least one point without worsening of steatohepatitis
A separate, longer-horizon endpoint assessed at week 240 tracks liver-related clinical events — progression to cirrhosis, hepatic decompensation, liver transplant, and MASH-related mortality — which is the piece that will determine whether histologic improvement at 72 weeks actually predicts the outcomes clinicians care about. Interim histologic results from ESSENCE's first part have been reported by the sponsor showing significant separation from placebo on both co-primary endpoints; full peer-reviewed publication and the week-240 outcomes data remain pending. Phase 2 data preceding ESSENCE, published by Newsome and colleagues in the New England Journal of Medicine, found NASH resolution without fibrosis worsening in 59% of participants on semaglutide 0.4 mg versus 17% on placebo (PMID 33185364) — the effect size that justified moving to a fibrosis-focused Phase 3 design.
Survodutide and the SYNCHRONY Program
Survodutide (BI 456906), a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, takes a mechanistically different approach. Adding glucagon receptor agonism is intended to increase hepatic fatty acid oxidation and energy expenditure on top of GLP-1-mediated appetite and glycemic effects — a rationale grounded in receptor pharmacology discussed in comparisons of single- versus dual-agonist mechanisms.
Survodutide's Phase 2 trial in MASH, published by Sanyal and colleagues in NEJM, randomized participants with F1-F3 fibrosis to placebo or one of three survodutide doses over 48 weeks. Fibrosis improvement of at least one stage without worsening of steatohepatitis occurred in 65.8% of participants at the highest dose versus 14.4% on placebo (PMID 38856224) — a larger separation on the fibrosis endpoint than most GLP-1-selective agents have reported at comparable trial durations. That signal moved survodutide into its Phase 3 SYNCHRONY program, which is structured as multiple sub-studies: a histology-based registration trial, a longer-term clinical outcomes trial, and a real-world evidence component. Enrollment across the SYNCHRONY sub-studies has been underway since 2023, with sites recruiting participants who have biopsy-confirmed F2-F3 fibrosis, similar in design to ESSENCE.
Tirzepatide's Path from Phase 2 to Phase 3
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced Phase 2 MASH data (SYNERGY-NASH) showing high rates of steatohepatitis resolution and fibrosis improvement across dose groups in participants with F2-F3 fibrosis over 52 weeks, reported by Sanyal and colleagues in NEJM in 2024. The magnitude of histologic response in that trial was broadly consistent with, and in some subgroup analyses exceeded, semaglutide's Phase 2 results, though cross-trial comparisons are limited by differences in population, biopsy timing, and pathologist scoring — a caveat that applies to every comparison in this therapeutic area given the absence of head-to-head trials.
Eli Lilly has indicated intent to advance tirzepatide into Phase 3 MASH testing, but as of this writing a fully enrolled, registration-track Phase 3 tirzepatide MASH trial with a posted primary completion date has not reached the same maturity as ESSENCE or SYNCHRONY. Clinicians tracking this program should verify current status directly on ClinicalTrials.gov before citing enrollment figures, since Phase 2-to-3 transitions in this class have moved faster than publication cycles can document.
Comparing Primary Endpoints Across Programs
Despite different mechanisms, the Phase 3 MASH trials in this class have converged on a similar endpoint structure, largely because it mirrors the framework FDA has already accepted for resmetirom:
- Histologic resolution — NASH/MASH resolution without worsening of fibrosis, scored on the NAFLD Activity Score (NAS) by central pathology, typically at week 72
- Fibrosis improvement — at least one-stage improvement on the NASH Clinical Research Network (CRN) fibrosis scale without worsening of steatohepatitis
- Long-term clinical outcomes — progression to cirrhosis, decompensation events, transplant, or death, assessed over 3-5 years in a subset of trial participants or an extension study
The first two endpoints function as accelerated-approval surrogates; the third is what regulators and clinicians ultimately need to know whether histologic improvement holds up as a proxy for reduced liver-related morbidity. This is the same evidentiary structure discussed in broader safety-monitoring guidance for GLP-1 class agents, and it is worth clinicians reviewing that monitoring framework alongside any NASH-specific trial data before extrapolating findings to individual patients.
What Remains Unclear
Several open questions limit how far current data can be extrapolated into practice. First, durability beyond 72 weeks is not yet established for any GLP-1-class agent in MASH — weight regain after treatment discontinuation, documented in obesity trials, raises the question of whether histologic gains persist or reverse if therapy stops. Second, sub-population response has not been fully characterized; early signals suggest attenuated fibrosis response in participants with type 2 diabetes and more advanced baseline fibrosis (F3 versus F2), though sample sizes in these subgroups remain small across published Phase 2 data. Third, biopsy-based endpoints carry inherent sampling variability — a limitation acknowledged in the FDA's own guidance on MASH drug development — meaning some proportion of apparent treatment effect reflects biopsy noise rather than true histologic change.
Adverse event profiles across these trials mirror what has been reported in cardiometabolic indications: gastrointestinal events (nausea, diarrhea, vomiting) are the most common reason for discontinuation, occurring more frequently at higher doses and during dose escalation. Monitoring protocols in these trials typically include liver enzymes, renal function, and gallbladder-related symptoms at defined intervals, consistent with monitoring recommendations covered in compound-specific reconstitution and handling literature for research-grade GLP-1 peptides, which is a distinct regulatory category from the pharmaceutical-grade products used in these trials.
Practical Next Step for Clinicians and Researchers
For a clinician or researcher trying to counsel a patient with biopsy-confirmed MASH today, the actionable step is to check the current recruiting status and eligibility criteria for ESSENCE, SYNCHRONY, and any open tirzepatide MASH sub-studies directly on ClinicalTrials.gov before referring a patient — enrollment windows, fibrosis-stage inclusion criteria, and site locations change frequently enough that secondhand summaries, including this one, should be verified against the primary registry entry at the time of referral. No GLP-1 receptor agonist currently carries an FDA-approved MASH indication, so any use for liver disease outside an active trial remains off-label and should be weighed individually against resmetirom and standard metabolic risk-factor management.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.